SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-046423
Filing Date
2024-04-22
Accepted
2024-04-22 16:10:07
Documents
2
Period of Report
2024-04-10

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 2557
2 EX-24.POA ntla-ex24_poa.htm EX-24.POA 9920
  Complete submission text file 0000950170-24-046423.txt   13954
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Issuer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139
Business Address
Dube Michael P (Reporting) CIK: 0002019493 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37766 | Film No.: 24861290